Analysis of other systemic symptoms assessed by the PLQS revealed that difficulty sleeping and changes in the frequency or urgency of urination also negatively correlated with anti-PAD2 antibodies in PTLD (Figure 4B). Here, PADI2 is linked to post-transplant lymphoproliferative disease.